We investigated the contribution of plasma folate de®ciency to hyperhomocysteinaemia in selected patient groups. Based on our observations, we have determined a lower folate reference interval cut-off using homocysteine as a metabolic marker of folate de®ciency. Four hundred and twenty-®ve consecutive plasma specimens from cardiology (n=120), haematology (n=190) and nephrology (n=115) patients were analysed for homocysteine and plasma folate concentrations. Healthy volunteers were used as controls (n=117). We observed elevated homocysteine values above our upper reference limit of 13 mmol/L in 20´1%, 28´4% and 74´8% of the cardiology, haematology and nephrology patients, respectively. All but 1´9% of the patients had plasma folate values greater than the lower reference interval limit (3´4 nmol/L) for our folate assay. The percentage of patients from cardiology and haematology clinics who were hyperhomocysteinaemic and had folate values > 15 nmol/L was 5´0% and 4´2%, respectively. In contrast, 58% of our nephrology patients with folate values > 15 nmol/L were hyperhomocysteinaemic. In all three groups, an inverse relationship was found between folate and homocysteine. The folate/homocysteine ratios in the patient groups were approximately one-third of the values observed in our control group. Folate de®ciency appears to be the primary cause of hyperhomocysteinaemia in our cardiology and thrombosis patients. However, severe folate de®ciency appears to be uncommon. The majority of our nephrology patients are hyperhomocysteinaemic without an apparent folate de®ciency. We conclude that raising the lower reference interval cut-off for folate to 15 nmol/L would help to identify individuals at risk for hyperhomocysteinaemia in our non-uraemic patient population. Increasing folate supplementation to maintain a plasma concentration above 15 nmol/L in cardiac, thrombosis and renal patients would greatly reduce the occurrence of hyperhomocysteinaemia in these patients.
INTRODUCTION
Hyperhomocysteinaemia is a risk factor for venous and arterial thrombosis. 1 Currently, it is unknown whether homocysteine is a contributing factor to vascular disease or if it is simply a proximal marker. Nonetheless, the measurement of homocysteine may be useful in detecting de®ciencies of the B vitamins, folate, cobalamin and pyridoxine. 2 This would be of bene®t since mathematically derived reference intervals for cobalamin and folate, sampled from apparently normal populations, do not re¯ect actual patient metabolic requirements. 3 It would be desirable to have assays that can indicate when an individual has a metabolic de®ciency of folate or cobalamin.
Cobalamin de®ciency can be detected by an elevation in both plasma homocysteine and methylmalonic acid. 4 The accumulation of homocysteine is the result of impaired recovery of methionine from homocysteine by methionine synthase (MS; EC 2.1.1.13), an enzyme that makes use of methylcyanocobalamin as a cofactor. The accumulation of methylmalonic acid is due to a de®ciency of adenosylcobalamin, a cofactor for the conversion of L-methylmalonyl-CoA to succinyl-CoA. An increase in the plasma concentration of these two metabolites typically precedes the development of megaloblastic anaemia. 4, 5 Folate de®ciency also causes mild hyperhomocysteinaemia; however, there is no concurrent increase in plasma methylmalonic acid. Homocysteine accumulates in folate de®ciency because there are insuf®cient quantities of the 5-methyltetrahydrofolate which are required to remethylate cobalamin in order to produce methionine via methionine synthase (Fig. 1) . The conversion of L-methylmalonyl-CoA to succinyl-CoA does not require folate; therefore methylmalonic acid does not accumulate.
Folate metabolic requirements are under genetic control. 6 Hepatic 5,10-methylenetetrahydrofolate is converted to 5-methyltetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR; EC 1.5.1.20). Figure 1 shows selected pathways for folate, methylation and transsulphuration pathways and their interrelationship. The 5-methyltetrahydrofolate species is then secreted with bile and is subsequently reabsorbed via the enterohepatic recirculation and distributed systemically. Individuals with the thermolabile phenotype of this enzyme have less circulating folate and reduced quantities of 5-methyltetrahydrofolate. 7 The 5-methyl species is required for methylation reactions; consequently, these individuals tend to have a higher concentration of plasma homocysteine and lower concentration of plasma folate. 7 The mutation responsible for the thermolabile form of the enzyme is a 677 cytosine (C) ? thymidine (T) transition that results in a valine substitution. 7 The presence of folate stabilizes the thermolabile variant. 7 Folate values greater than 15´4 nmol/L are thought to neutralize the effects of this phenotype. 7 The 677T substitution is very common in Caucasians, 7 and approximately 12´4% of our population are homozygous for this allele. 8 If homocysteine was shown to be useful as a metabolic marker for B vitamin status, clinicians might order this test more frequently. Therefore, prior to assessing the cost-effectiveness of homocysteine testing in patients with folate de®ciency, it would be useful to know the occurrence of hyperhomocysteinaemia in a patient population, the contribution of folate de®ciency to hyperhomocysteinaemia and the predictive value of this metabolite to detect folate de®ciency.
We have determined the folate and homocysteine values for 425 plasma specimens from our cardiology, haematology and nephrology units. The frequency of hyperhomocysteinaemia was determined in these groups. The contribution of folate de®ciency to hyperhomocysteinaemia was estimated. We then determined a lower reference interval cut-off for plasma folate concentration based on the observed homocysteine values in our study groups. From these estimates, we determined what percentage of our patients would probably bene®t from folate supplementation. We also determined the predictive value of homocysteine measurements for folate de®ciency in these groups.
METHODS
All procedures were performed in accordance with the policies of the Institutional Review Board of the Ottawa Hospital±Civic Campus.
EDTA-treated plasma was obtained from 425 patient specimens from the cardiology, haematology and nephrology units of the Ottawa Hospital±Civic and General Campuses. In most cases patients were counselled to fast; however, compliance was not determined prior to phlebotomy. EDTA-treated plasma from healthy volunteers (n=117) was used as a control. Fasting was not speci®ed for the control group. Individuals were asked not to volunteer if they were aware of a pre-existing cardiac, hepatic or renal illness. They were also asked not to volunteer if they were taking over-the-counter or prescription medications. All specimens were placed on ice with the plasma separated within 1 h of collection. Plasma aliquots were frozen at 3 20 Ê C until analysed. Total homocysteine was measured using one of two methods: a previously described high-performance liquid chromatography (HPLC) method, employing sodium borohydride reduction, monochlorobimane derivatization, reverse-phase separation and¯uorescence detection, 9 and the Abbott IMx [ automated assay. These assays were found to provide similar results because the slope, y-intercept and correlation coef®cient for the comparison of the homocysteine results between the HPLC and IMx methods were nearly ideal. 10 The upper reference interval for homocysteine in both assays was 13 mmol/L. Table 1 lists the mean folate and homocysteine values for each group. The mean folate values for the cardiology and haematology groups were signi®cantly lower than those of the control group, whereas the mean folate value for the nephrology group was similar to that of the control group. Mean homocysteine values for all three patient groups were signi®cantly higher than those of the control group. The mean homocysteine value of our nephrology group was greater than our upper reference interval (13 mmol/L). The mean folate/homocysteine ratios for all three patient groups were approximately one-third of the values obtained for controls.
RESULTS
The plots of plasma folate versus homocysteine are presented in Fig. 2 . Only 1´9% of the patients had folate concentrations below our current lower reference interval cut-off of 3´4 nmol/L. However, 20´1%, 28´4% and 74´8% of the cardiology, haematology and nephrology patients, respectively, had homocysteine values greater than 13 mmol/L and folate values above our current lower reference interval (3´4 nmol/L).
Few hyperhomocysteinaemic patients had folate values above 15 nmol/L. The percentages of haematology and cardiology patients with both elevated homocysteine (> 13 mmol/L) and folate (> 15 nmol/L) values were 4´2% and 5´0%, respectively.
Regression curves were generated using the Passing±Bablok equation and the least-squares regression equation (Table 2) . A negative correlation existed between folate values < 15 nmol/L and homocysteine values. However, the data deviated from linearity and did not ®t the regression model. Non-linear equations were generated for each plot. Suitable curve models could not be used to ®t the data because of patients having both elevated homocysteine and folate levels. An exponential decay curve was found to ®t the data after trimming the points with folate values above 15 nmol/L. The linear regression line equations are presented in Table  2 . The linear regression plots and the decay curves are presented in Fig. 2 . Table 3 lists the sensitivity and speci®city for homocysteine and various folate cut-off values.
DISCUSSION
The occurrence of hyperhomocysteinaemia in our patient groups was high. In contrast, hyperhomocysteinaemia was rare in our control group, with only one individual in 117 (0´9%) having a plasma homocysteine above 13 mmol/L. This person had chosen to ignore the request not to volunteer if there was a pre-existing major illness. He later acknowledged having cardiovascular disease and had undergone recent coronary artery bypass graft surgery. The high rate of occurrence of hyperhomocysteinaemia in our patient groups is similar to the ®ndings of Boers, 11 who observed elevated homocysteine in 21% of coronary heart disease patients and 32% of venous thrombosis patients. Blacher et al. also observed that a signi®cant percentage (15%) of their coronary heart disease patients were hyperhomocysteinaemic. 12 This is contradictory to the study published by Amundsen et al., 13 who found no difference in fasting homocysteine levels between controls and coronary heart disease patients.
In our study, hyperhomocysteinaemia correlated with reduced folate values. Surprisingly, few patients were found to have outright folate be a ceiling beyond which folate does not further reduce homocysteine levels. This is re¯ected in the mean folate value of these patients, which is similar to the mean value observed for the control group. Impaired homocysteine metabolism could possibly be due to any number of factors, including alterations in the folate± MTHFR, cobalamin±MS and pyridoxine± cystathionine b-synthase (CBS) pathways. The CBS pathway is part of the transulphuration pathway. The ability to metabolize homocysteine in these patients may simply be at a maximal enzyme activity level. These patients may also have a reduction in the activity of the renal transulphuration (CBS) pathway, coincident to loss of functional renal tissue. Although the mean folate concentration for nephrology patients was similar to that of the control group, the mean folate/homocysteine ratios between groups were different. All three patient groups had ratios that were substantially lower than those of the control group. This re¯ects an increased body burden of homocysteine per unit quantity of folate. Homocysteine in plasma re¯ects the status or activity in only one folate-dependent pathway. Elevated homocysteine levels can indicate reduced regeneration of methionine; however, this can also be due to vitamin B 12 de®ciency or to genetic defects in the enzymes involved in remethylation. Moreover, a de®ciency in pyridoxine or a defect in the enzymes of the transulphuration pathway can also contribute to hyperhomocysteinaemia. These confounding factors make it dif®cult to prove conclusively that folate de®ciency alone is the cause of homocysteinaemia in a particular patient. The folate/ homocysteine ratio may prove useful in determining a relative lack of folate in the absence of severe folate de®ciency.
The mean age of each patient group was between 6´8 and 17´2 years older than the control group. However, age probably did not signi®cantly in¯uence the homocysteine values observed in each group. The slope of the regression line, age versus homocysteine, did not show a signi®cant deviation from zero for any of the patient groups (data not shown). Additionally, there were no signi®cant differences between homocysteine values when sorted by age within the control group.
Regression analysis ( Table 2 and Fig. 1 ) for each patient group provided further evidence that the predominant cause of hyperhomocysteinaemia was folate de®ciency. Negative slopes were observed for each group using the Passing± Bablok or least-squares methods of regression. The Passing±Bablok method was used to determine the slope, since that method is less sensitive to the distribution of the data. The data did not properly ®t with either of the two linear equations and the estimates of the slopes were invalid; however, a negative correlation was shown to exist. The low values of the correlation coef®cient (r) are indicative of the different groups presenting with hyperhomocysteinaemia. The predominant group is folate de®cient and a smaller subset has normal folate; however, homocysteine metabolism is impaired for some other reason. The equation that appeared to ®t best with the data was an exponential decay curve, but only after the data from patients with folate values above 15 nmol/L were trimmed. This was because, in both the cardiology and the haematology groups, there was a small percentage of patients with hyperhomocysteinaemia, which appeared to be unrelated to folate concentration. Table 3 lists the sensitivity, speci®city, positive predictive value and negative predictive value for hyperhomocysteinaemia as a predictor of folate de®ciency. Speci®city at various cut-off folate concentrations shows that homocysteine is a poor predictor of folate de®ciency in terms 
² Equations fail test for linearity.
of speci®city. There are a number of false positive results due to other causes of hyperhomocysteinaemia. In the extreme case illustrated with nephrology patients it appears that folate de®ciency is not the cause of hyperhomocysteinaemia; however, it is not known how ef®ciently these patients are capable of utilizing the folate available to them. At the lower range of plasma folate concentrations encountered in our patients, we also saw a large overlap of hyperhomocysteinaemic and nonhyperhomocysteinaemic patients. Such an overlap is consistent with the variable metabolic requirements of folate in the population. In part, this is probably due to the MTHFR 677T allele that results in a thermolabile MTHFR phenotype with reduced enzyme activity. 7 MTHFR genotyping was not available for this study; however, we have since found that our homozygosity rate is 14% for the MTHFR 677T allele in our thrombosis patients and approximately 12% in normal individuals. Therefore, it is reasonable to assume that signi®cant numbers of our hyperhomocysteinaemic patients possess the thermolabile MTHFR phenotype. 8 Non-fasting homocysteine values in the control group were found to be signi®cantly lower than the homocysteine values for each disease group. Consensus has not been reached as to what is the preferred specimen to be tested for homocysteine measurement; however, evidence suggests that postprandial homocysteine values are similar to fasting values. Ubbink et al. 16 showed that food consumption did not affect homocysteine concentrations in a control group. Candito et al. 17 obtained similar results with cardiovascular disease patients; however, there was a slight, but statistically signi®cant, increase in the 2 h postprandial homocysteine in patients with the MTHFR 677TT genotype (13´62 versus 12´25 mmol/L; P40´02). The methionine content of the meals consumed by Candito's test subjects was 1´2±1´5 g. In contrast, a typical methionineloading test uses 0´1 g/kg methionine, or roughly ®ve times as much methionine.
It is apparent that homocysteine measurement should not replace the folate assay for the assessment of folate status. Homocysteine measurement should serve as an adjunct to the folate assessment when attempting to determine whether or not an individual is metabolically de®cient. Considering the large percentage of hyperhomocysteinaemic patients with folate concentrations below 15 nmol/L, it may be more cost-effective to ®rst assess plasma folate concentration and, when required, to treat the patient with vitamin supplementation or diet modi®cation. Then, when subsequent testing shows that the folate level is above 15 nmol/L, measure homocysteine to rule out hyperhomocysteinaemia secondary to causes other than folate de®ciency. A proposed algorithm for the investigation of hyperhomocysteinaemia in adults is shown in Fig. 3 . Assuming patients would not have homocysteine measured until folate concentrations were above 15 nmol/L, this algorithm would likely eliminate a signi®cant number of patients with elevated homocysteine levels and would therefore reduce subsequent follow-up reanalysis. To illustrate this, we found that a total of 23% and 29´3% of our cardiac and thrombosis patients, respectively, were hyperhomocysteinaemic (> 13 mmol/L). The total percentage of all cardiac and thrombosis patients with folate values below 15 nmol/L is 80´3% and 75´9%, respectively. Therefore, if this algorithm were followed, only 19´7% and 24´1% of all initial requests for homocysteine analysis would be processed. Of these initial requests that were processed we would expect a rate of hyperhomocysteinaemia of 25´4% and 17´4% for cardiac and thrombosis patients, representing 5´0% and 4´2% of all requests. This is the group that is hyperhomocysteinaemic from causes other than folate de®ciency. This small percentage of patients is hyperhomocysteinaemic due to either inherited defects in the enzymes involved with homocysteine metabolism, vitamin B 12 de®ciency, renal insuf®ciency or drugs that promote the accumulation of homocysteine. The patients that are observed to be folate de®cient on the ®rst encounter should be treated for folate de®ciency and then reanalysed after a suitable period of time.
In any event, the lower reference interval for plasma folate should be adjusted upwards to 15 nmol/L, as this value appears to minimize the number of homocysteinaemic patients in our population. Above 15 nmol/L the thermolabile variant of MTHFR does not appear to in¯uence homocysteine metabolism. 7 Others have suggested a lower reference interval value of 10 nmol/L for folate. 18 In our cardiac and haematology patient groups, we encountered a considerable proportion of patients with homocysteine and folate concentrations above 13 mmol/L and 10 nmol/L, respectively.
CONCLUSIONS
Hyperhomocysteinaemia is common in our cardiology, nephrologyand haematology groups. The major contributor to hyperhomocysteinaemia appears to be a relative lack of folate, particularly in the cardiac and haematology patients. However, we cannot accurately predict folate de®ciency using homocysteine measurement. Below a plasma folate concentration of 15 nmol/L, the incidence of hyperhomocysteinaemia is quite high. Therefore, in non-uraemic patients, we propose that a folate cut-off value of no less than 15 nmol/L be applied to discriminate hyperhomocysteinaemia due to folate de®ciency and other causes such as vitamin B 12 de®ciency.
